Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering. [1]
Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering. [1]
Drebin earned his MD and Ph.D. from Harvard Medical School, before completing his general surgery residency, and surgical oncology fellowship, at Johns Hopkins Medical School. [2] His Ph.D. research, performed with Mark Greene and Robert Weinberg, involved the creation of monoclonal antibodies targeting the Her2/neu protein and demonstrating in preclinical models that such antibodies could inhibit cancer cell growth in vitro and in vivo . [3] This work was focused on targeted cancer therapy and the creation of the drugs trastuzumab (Herceptin) and pertuzumab (Perjeta). [4]
In 1995, after finishing his residency, Drebin became an assistant professor of surgery at Washington University School of Medicine. [5] He became an associate professor in 1999, and then a full Professor of Surgery and of Molecular Biology & Pharmacology in 2002. [1] Drebin began working at Penn Medicine in 2004 when he was hired as Chief of the Division of Gastrointestinal Surgery. [6] In 2009, he was named chair of the department. [1] [6] While there, he joined a Stand Up to Cancer “Dream Team” against pancreatic cancer as a co-Principal Investigator alongside Craig B. Thompson. [7] [8] [9] In 2017, Drebin moved to Memorial Sloan Kettering to become Department of Surgery Chair. [1] In addition to his responsibilities as chair, he provides surgical treatments for patients with pancreatic, gallbladder, bile duct, liver, and stomach cancers. His research focuses on the development of new targeted therapies. [1]
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 72 National Cancer Institute-designated Comprehensive Cancer Centers. It had already been renamed and relocated, to its present site, when the Sloan-Kettering Institute for Cancer Research was founded in 1945, and built adjacent to the hospital. The two medical entities formally coordinated their operations in 1960, and formally merged as a single entity in 1980. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.
Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.
Monica Morrow is a breast cancer surgeon and Chief of Breast Surgery at Memorial Sloan-Kettering Cancer Center in Manhattan, NY. Her first day seeing patients in clinic as Chief at MSKCC was Tuesday, February 19, 2008. She formerly served as the chairman of surgical oncology at the Fox Chase Cancer Center. She is the President-elect of the Society for Surgical Oncology.
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
William S. Breitbart, FAPM, is an American psychiatrist in Psychosomatic Medicine, Psycho-oncology, and Palliative Care. He is the Jimmie C Holland Chair in Psychiatric Oncology, and the Chief of the Psychiatry Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, He is a Professor of Clinical Psychiatry at Weill Medical College of Cornell University. He was president of the Academy of Psychosomatic Medicine, and the Editor-in-Chief of Palliative and Supportive Care.
Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.
The Band of Parents is a 501(c)(3) nonprofit organization. Formed in July 2007 and incorporated in October 2007, it was founded by approximately 100 parents of young children with neuroblastoma who were treated at Memorial Sloan Kettering Cancer Center (MSKCC). Its purpose is to fund the development of new therapies for neuroblastoma that would not otherwise be pursued by research institutions or the pharmaceutical industry. The organization has become the largest single funder of neuroblastoma research at MSKCC.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Peter T. Scardino is an American cancer surgeon, researcher, and author expert in genitourinary and urological cancers particularly cancer of the prostate. He is chair of the Department of Surgery at Memorial Sloan Kettering Cancer Center.
John H. Healey is an American cancer surgeon, researcher, and expert in the surgical treatment of benign and malignant bone tumors and other musculoskeletal cancers. He serves as Chair of the Orthopaedic Service and Stephen P. McDermott Chair in Surgery at Memorial Sloan-Kettering Cancer Center (MSKCC), as well as Professor of Surgery at Weill Cornell Medical College, in New York, NY.
Kenneth Offit is an American cancer geneticist and oncologist known for his discoveries with respect to the genetic bases of breast, colorectal, and lymphoid cancers. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute and Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College. He was previously a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.
David A. Scheinberg is an American physician, scientist, drug developer, and entrepreneur, who is currently Vincent Astor Chair, and Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK). He is a pioneer and inventor of targeted alpha particle therapies and alpha particle generators for use in patients with cancer.
Viviane Tabar is an American neurosurgeon, the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York since 2017.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.
Valerie W Rusch, MD, FACS, is an American thoracic surgeon who is currently the Miner Family Chair for Intrathoracic Cancers and Vice Chair for Clinical Research, Department of Surgery, at Memorial Sloan Kettering Cancer Center.
| International | |
|---|---|
| National | |
| Academics | |
